New Delhi: Bharat Biotech’s COVID-19 vaccine Covaxin recommended by expert panel for phase II/III clinical trials on 2 to 18 year-olds, said Sources.
Bharat Biotech on Tuesday informed that the firm has been supplying its COVID-19 vaccine Covaxin directly to 18 states since May 1.
“Unflinching in our efforts, we will continue the steady supply of our vaccine,” the company tweeted. The pharma firm also appealed to people to vaccinate themselves and their family members.
Maharashtra, Madhya Pradesh, Bihar, Uttar Pradesh, West Bengal, and Assam are among the 18 states where the company has been supplying the vaccines directly.
Covaxin is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech in association with the Indian Council of Medical Research and the National Institute of Virology.
This is a developing story.
